135 related articles for article (PubMed ID: 233160)
1. Low dose fluphenazine decanoate in maintenance treatment of schizophrenia.
Kane JM; Rifkin A; Quitkin F; Nayak D; Saraf K; Ramos-Lorenzi JR; Klein DF; Sachar EJ
Psychiatry Res; 1979 Dec; 1(3):341-8. PubMed ID: 233160
[TBL] [Abstract][Full Text] [Related]
2. A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients.
Wistedt B
Acta Psychiatr Scand; 1981 Jul; 64(1):65-84. PubMed ID: 7032224
[TBL] [Abstract][Full Text] [Related]
3. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Chouinard G; Annable L; Campbell W
J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
[TBL] [Abstract][Full Text] [Related]
4. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia.
Kane JM; Rifkin A; Quitkin F; Nayak D; Ramos-Lorenzi J
Arch Gen Psychiatry; 1982 Jan; 39(1):70-3. PubMed ID: 6275811
[TBL] [Abstract][Full Text] [Related]
5. The social value of fluphenazine decanoate.
Stevens B
Acta Psychiatr Belg; 1976; 76(5):792-804. PubMed ID: 799897
[TBL] [Abstract][Full Text] [Related]
6. Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia.
Marder SR; Wirshing WC; Van Putten T; Mintz J; McKenzie J; Johnston-Cronk K; Lebell M; Liberman RP
Arch Gen Psychiatry; 1994 Apr; 51(4):280-7. PubMed ID: 8161288
[TBL] [Abstract][Full Text] [Related]
7. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
Odejide OA; Aderounmu AF
J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
[TBL] [Abstract][Full Text] [Related]
8. A double-blind comparison of fluphenazine decanoate and flupenthixol decanoate in the treatment of acute schizophrenia.
Johnson DA; Malik NA
Acta Psychiatr Scand; 1975 May; 51(4):257-67. PubMed ID: 1096536
[TBL] [Abstract][Full Text] [Related]
9. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
[TBL] [Abstract][Full Text] [Related]
10. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
[TBL] [Abstract][Full Text] [Related]
11. Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology.
Wistedt B; Ranta J
Acta Psychiatr Scand; 1983 Jun; 67(6):378-88. PubMed ID: 6349256
[TBL] [Abstract][Full Text] [Related]
12. Fluphenazine decanoate and fluphenazine enanthate in the out-patient management of chronic schizophrenia.
MacCrimmon DJ; Saxena B; Foley P; Grof P
Neuropsychobiology; 1978; 4(6):360-5. PubMed ID: 692838
[TBL] [Abstract][Full Text] [Related]
13. A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients.
Walker CA
Pharmatherapeutica; 1983; 3(5):289-93. PubMed ID: 6133287
[TBL] [Abstract][Full Text] [Related]
14. Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data.
Rifkin A; Quitkin F; Klein DF
Arch Gen Psychiatry; 1977 Oct; 34(10):1215-9. PubMed ID: 199129
[TBL] [Abstract][Full Text] [Related]
15. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry.
Hirsch SR; Gaind R; Rohde PD; Stevens BC; Wing JK
Br Med J; 1973 Mar; 1(5854):633-7. PubMed ID: 4571196
[TBL] [Abstract][Full Text] [Related]
16. Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates.
McLaren S; Cookson JC; Silverstone T
Int Clin Psychopharmacol; 1992 Nov; 7(2):67-72. PubMed ID: 1487623
[TBL] [Abstract][Full Text] [Related]
17. A long term comparative trial of penfluridol and fluphenazine decanoate in schizophrenic outpatients.
Iqbal MJ; Young MA; Charles J; Elgart B; Von Greiff H; Simpson GM
J Clin Psychiatry; 1978 Apr; 39(4):375-9. PubMed ID: 580285
[TBL] [Abstract][Full Text] [Related]
18. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
Wistedt B
Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():15-23. PubMed ID: 3549878
[TBL] [Abstract][Full Text] [Related]
19. The effect of fluphenazine upon social and vocational functioning in remitted schizophrenics.
Rifkin A; Quitkin F; Kane J; Klein DF; Ross D
Biol Psychiatry; 1979 Jun; 14(3):499-508. PubMed ID: 224958
[TBL] [Abstract][Full Text] [Related]
20. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride.
Hogarty GE; Schooler NR; Ulrich R; Mussare F; Ferro P; Herron E
Arch Gen Psychiatry; 1979 Nov; 36(12):1283-94. PubMed ID: 227340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
